青光眼患者滴用前列腺素类似物后瞳距缩短
这项回顾性比较病例系列纳入152例青光眼患者和61例未治疗对照,发现持续滴用前列腺素类似物2–24个月后瞳距(IPD)显著缩短(P<0.001,-0.80±2.1 mm),对照组无变化;比马前列素组IPD缩短幅度显著大于其他前列腺素类似物(P<0.001),自动验光仪测量IPD或可作为前列腺素相关眶周病变(PAP)的客观指标。
要点
- 持续滴用前列腺素类似物后IPD显著缩短,对照组无变化。
- 比马前列素引起的IPD缩短幅度显著大于其他前列腺素类似物。
- 自动验光仪测量IPD无创、即时,或可作为PAP的客观数值指标。
核心结论
- 持续滴用前列腺素类似物24个月内IPD显著缩短,比马前列素效应显著大于其他前列腺素类似物。
- 自动验光仪测量IPD无创、即时,或可作为前列腺素相关眶周病变的客观数值指标。
研究设计与样本
- 回顾性比较病例系列,纳入152例机构青光眼患者,另设61例未治疗患者作为对照。
- 纳入标准为双眼视力超过10/20且观察期间无眼内手术。
主要发现
- 治疗组IPD治疗后显著缩短(P<0.001,-0.80±2.1 mm),对照组IPD无变化(0.05±0.96 mm,P=0.69)。
- 比马前列素组IPD变化(-2.20±0.97 mm)显著大于其他前列腺素类似物组(-0.65±2.09 mm)(P<0.001)。
- 治疗后眼压显著下降(P<0.001,-3.7±4.3 mm Hg),屈光误差无显著变化(P<0.099,-0.07±0.69 D)。
- 比马前列素、曲伏前列素、拉坦前列素、他氟前列素组IPD下降≥2 mm的比例分别为85.7%、20.0%、18.2%、17.2%。
- 上述四组IPD下降≥3 mm的比例分别为35.7%、12.0%、14.5%、12.1%;对照组对应特异度分别为93.4%和100%。
关键数值与推荐
- IPD下降≥2 mm作为阈值时,对照组特异度为93.4%;下降≥3 mm时,对照组特异度为100%。
临床怎么用
- 对使用前列腺素类似物的青光眼患者,可用自动验光仪测量IPD以客观监测前列腺素相关眶周病变。
- 比马前列素治疗者IPD缩短更明显,临床随访中应予以关注。
局限性
- 回顾性设计,为非随机比较,可能存在选择偏倚。
- 观察期为治疗后2–24个月,长期变化未涵盖。
- 仅纳入视力超过10/20且无眼内手术者,结论外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate changes in the interpupillary distance (IPD) after continual instillation of topical prostaglandin analogs (PGAs) in glaucoma patients as an objective indicator of prostaglandin-associated periorbitopathy (PAP). DESIGN: Retrospective, comparative case series. METHODS: A total of 152 institutional patients with glaucoma were enrolled in this study. Inclusion criteria were visual acuities exceeding 10/20 bilaterally and no intraocular surgery during observation. Intervention/observation procedures: First-time bilateral instillation of bimatoprost, travoprost, latanoprost, or tafluprost and IPDs measured by automatic refractometry. IPDs, intraocular pressures (IOPs), and refractive errors were measured before and after continual drug administration (treatment, 2-24 months). MAIN OUTCOME MEASUREMENTS: Post-treatment changes in IPDs. A total of 61 untreated patients served as controls. RESULTS: The IPDs shortened significantly (P < 0.001) after treatment (-0.80 ± 2.1 mm); the IPDs of control subjects remained unchanged (0.05 ± 0.96 mm; P = 0.69). The IPD change after bimatoprost instillation (-2.20 ± 0.97 mm) was significantly (P < 0.001) greater than with other PGAs (-0.65 ± 2.09 mm). The IOPs decreased significantly (P < 0.001) (-3.7 ± 4.3 mm Hg); the refractive errors did not change significantly (P < 0.099) (-0.07 ± 0.69 diopter) post-treatment. The percentages of subjects with 2-mm or greater decreases in IPD after bimatoprost, travoprost, latanoprost, or tafluprost were 85.7%, 20.0%, 18.2%, and 17.2%, respectively, and with 3-mm or greater decreases in IPD 35.7%, 12.0%, 14.5%, and 12.1%, respectively. The specificities were 93.4% and 100% in the control group, respectively, with IPD threshold changes of 2 and 3 mm or more, respectively. CONCLUSIONS: The IPD decreased significantly after topical PGAs within 24 months. The effect was significantly greater with bimatoprost than with other PGAs. The noninvasive, immediate automatic refractometry measurement may be an objective numerical indicator of PAP.
引用
- Sano I, Takahashi H, Inoda S, et al. Shortening of Interpupillary Distance after Instillation of Topical Prostaglandin Analog Eye Drops. Am J Ophthalmol. 2019. PMID: 30902695. doi:10.1016/j.ajo.2019.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。